{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:17:56Z","timestamp":1773307076888,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG042178, AG047812, NS105473, AG060767 and AG069333"],"award-info":[{"award-number":["AG042178, AG047812, NS105473, AG060767 and AG069333"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["AG063162"],"award-info":[{"award-number":["AG063162"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12035-020-02074-2","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T02:02:54Z","timestamp":1597716174000},"page":"4856-4877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection"],"prefix":"10.1007","volume":"57","author":[{"given":"Jasvinder Singh","family":"Bhatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurjit Kaur","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naina","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arubala P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-9948","authenticated-orcid":false,"given":"P. Hemachandra","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"4","key":"2074_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ajcp\/aqaa029","volume":"153","author":"J Guarner","year":"2020","unstructured":"Guarner J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153(4):420\u2013421. https:\/\/doi.org\/10.1093\/ajcp\/aqaa029","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"2074_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten C, G\u00fcnther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, Rabenau H, Panning M et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967\u20131976","journal-title":"N Engl J Med"},{"issue":"20","key":"2074_CR3","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","volume":"348","author":"TG Ksiazek","year":"2003","unstructured":"Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953\u20131966","journal-title":"N Engl J Med"},{"issue":"19","key":"2074_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa1211721","journal-title":"N Engl J Med"},{"issue":"10223","key":"2074_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497\u2013506","journal-title":"Lancet"},{"key":"2074_CR6","volume-title":"WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS): updated recommendations, October 2004","author":"World Health Organization","year":"2004","unstructured":"World Health Organization (2004) WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS): updated recommendations, October 2004. World Health Organization, Geneva"},{"issue":"4","key":"2074_CR7","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.26355\/eurrev_202002_20379","volume":"24","author":"SA Meo","year":"2020","unstructured":"Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W et al (2020) Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 24(4):2012\u20132019. https:\/\/doi.org\/10.26355\/eurrev_202002_20379","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"2074_CR8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi Z-L (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17(3):181\u2013192","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2074_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Med Res 7(1):11. https:\/\/doi.org\/10.1186\/s40779-020-00240-0","journal-title":"Military Med Res"},{"issue":"10223","key":"2074_CR10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF-W Chan","year":"2020","unstructured":"Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514\u2013523","journal-title":"Lancet"},{"key":"2074_CR11","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia. N Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"key":"2074_CR12","unstructured":"World Health Organization (2020) Coronavirus disease (COVID-19) outbreak. URL https:\/\/www.whoint\/emergencies\/diseases\/novel-coronavirus-2019 Accessed March"},{"issue":"4","key":"2074_CR13","first-page":"2012","volume":"24","author":"S Meo","year":"2020","unstructured":"Meo S, Alhowikan A, Al-Khlaiwi T, Meo I, Halepoto D, Iqbal M, Usmani A, Hajjar W et al (2020) Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 24(4):2012\u20132019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2074_CR14","unstructured":"World Health Organization (2020) Coronavirus disease 2019 (COVID-19): situation report, 194 (1st Aug 2020)."},{"issue":"10223","key":"2074_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"2074_CR16","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1056\/NEJMc2005203","volume":"382","author":"AP Zavascki","year":"2020","unstructured":"Zavascki AP, Falci DR (2020) Clinical characteristics of Covid-19 in China. N Engl J Med 382:1859\u20131862. https:\/\/doi.org\/10.1056\/NEJMc2005203","journal-title":"N Engl J Med"},{"key":"2074_CR17","doi-asserted-by":"publisher","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2002032, 382, 1708, 1720","DOI":"10.1056\/NEJMoa2002032"},{"issue":"3","key":"2074_CR18","first-page":"135","volume":"33","author":"PC Passarelli","year":"2020","unstructured":"Passarelli PC, Lopez MA, Mastandrea Bonaviri GN, Garcia-Godoy F, D'Addona A (2020) Taste and smell as chemosensory dysfunctions in COVID-19 infection. Am J Dent 33(3):135\u2013137","journal-title":"Am J Dent"},{"key":"2074_CR19","doi-asserted-by":"publisher","unstructured":"Dawson P, Rabold EM, Laws RL, Conners EE, Gharpure R, Yin S, Buono SA, Dasu T et al (2020) Loss of taste and smell as distinguishing symptoms of COVID-19. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa799","DOI":"10.1093\/cid\/ciaa799"},{"key":"2074_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/oby.22809","volume":"28","author":"JF Gautier","year":"2020","unstructured":"Gautier JF, Ravussin Y (2020) A new symptom of COVID-19: loss of taste and smell. Obesity. 28:848. https:\/\/doi.org\/10.1002\/oby.22809","journal-title":"Obesity."},{"key":"2074_CR21","doi-asserted-by":"publisher","unstructured":"Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for C (2020) Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J https:\/\/doi.org\/10.1183\/13993003.00547-2020, 55, 2000547","DOI":"10.1183\/13993003.00547-2020"},{"issue":"5","key":"2074_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11912-020-00934-7","volume":"22","author":"R Gosain","year":"2020","unstructured":"Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS (2020) COVID-19 and cancer: a comprehensive review. Curr Oncol Rep 22(5):53. https:\/\/doi.org\/10.1007\/s11912-020-00934-7","journal-title":"Curr Oncol Rep"},{"key":"2074_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","volume":"31","author":"L Zhu","year":"2020","unstructured":"Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H et al (2020) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 31:1068\u20131077.e3. https:\/\/doi.org\/10.1016\/j.cmet.2020.04.021","journal-title":"Cell Metab"},{"key":"2074_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","volume":"146","author":"X Li","year":"2020","unstructured":"Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146:110\u2013118. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.006","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2074_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.micinf.2020.01.004","volume":"22","author":"J Chen","year":"2020","unstructured":"Chen J (2020) Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect 22(2):69\u201371. https:\/\/doi.org\/10.1016\/j.micinf.2020.01.004","journal-title":"Microbes Infect"},{"issue":"7440","key":"2074_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA et al (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251\u2013254. https:\/\/doi.org\/10.1038\/nature12005","journal-title":"Nature"},{"issue":"6965","key":"2074_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450\u2013454. https:\/\/doi.org\/10.1038\/nature02145","journal-title":"Nature"},{"issue":"4","key":"2074_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W et al (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424\u2013432. https:\/\/doi.org\/10.1002\/jmv.25685","journal-title":"J Med Virol"},{"issue":"1","key":"2074_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JF Chan","year":"2020","unstructured":"Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9(1):221\u2013236. https:\/\/doi.org\/10.1080\/22221751.2020.1719902","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"2074_CR30","doi-asserted-by":"publisher","first-page":"e00221-00218","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9(2):e00221-00218","journal-title":"mBio"},{"key":"2074_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/CM9.0000000000000722","volume":"133","author":"LL Ren","year":"2020","unstructured":"Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y et al (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J 133:1015\u20131024. https:\/\/doi.org\/10.1097\/CM9.0000000000000722","journal-title":"Chin Med J"},{"issue":"10224","key":"2074_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565\u2013574. https:\/\/doi.org\/10.1016\/s0140-6736(20)30251-8","journal-title":"Lancet"},{"key":"2074_CR33","doi-asserted-by":"publisher","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State - nCo VCIT (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382 (10):929\u2013936. https:\/\/doi.org\/10.1056\/NEJMoa2001191","DOI":"10.1056\/NEJMoa2001191"},{"issue":"3","key":"2074_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijpddr.2018.10.002","volume":"8","author":"ACC Aguiar","year":"2018","unstructured":"Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, Guedes JS, Meneghetti MR et al (2018) Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 8(3):459\u2013464. https:\/\/doi.org\/10.1016\/j.ijpddr.2018.10.002","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"3","key":"2074_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res 30(3):269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"2074_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.7326\/M20-1334","volume":"172","author":"J Yazdany","year":"2020","unstructured":"Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med 172:754\u2013755. https:\/\/doi.org\/10.7326\/M20-1334","journal-title":"Ann Intern Med"},{"key":"2074_CR37","doi-asserted-by":"publisher","unstructured":"Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents:105932. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105932","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"key":"2074_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/cid\/ciaa321","volume":"71","author":"M Guastalegname","year":"2020","unstructured":"Guastalegname M, Vallone A (2020) Could chloroquine \/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis 71:888\u2013889. https:\/\/doi.org\/10.1093\/cid\/ciaa321","journal-title":"Clin Infect Dis"},{"key":"2074_CR39","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown AJ, Won JJ, Graham RL, Dinnon KH III, Sims AC, Feng JY, Cihlar T, Denison MR et al (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res 169:104541","journal-title":"Antivir Res"},{"issue":"12","key":"2074_CR40","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T et al (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci 117(12):6771\u20136776","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2074_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, Sch\u00e4fer A, Won J, Brown AJ, Montgomery SA, Hogg A et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11(1):1\u201314","journal-title":"Nat Commun"},{"issue":"24","key":"2074_CR42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D et al (2019) A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381(24):2293\u20132303","journal-title":"N Engl J Med"},{"issue":"3","key":"2074_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19(3):149\u2013150. https:\/\/doi.org\/10.1038\/d41573-020-00016-0","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2074_CR44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"K Rainsford","year":"2015","unstructured":"Rainsford K, Parke AL, Clifford-Rashotte M, Kean W (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231\u2013269","journal-title":"Inflammopharmacology"},{"issue":"6","key":"2074_CR45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","volume":"68","author":"S JCD","year":"2013","unstructured":"JCD S, Mariz HA, LFd RJ, PSSd O, Dantas AT, ALBP D, IdR P, Galdino SL et al (2013) Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics 68(6):766\u2013771","journal-title":"Clinics"},{"issue":"2","key":"2074_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","volume":"42","author":"I Ben-Zvi","year":"2012","unstructured":"Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42(2):145\u2013153","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"2074_CR47","first-page":"983","volume":"25","author":"DD Gladman","year":"1998","unstructured":"Gladman DD, Urowitz MB, Senecal JL, Fortin PJ, Petty RE, Esdaile JM, Carrette S, Edworthy SM et al (1998) Aspects of use of antimalarials in systemic lupus erythematosus. J Rheumatol 25(5):983\u2013985","journal-title":"J Rheumatol"},{"issue":"2","key":"2074_CR48","first-page":"39","volume":"52","author":"JK Taylor","year":"2011","unstructured":"Taylor JK, McMurray RV (2011) Medical therapy for systemic lupus erythematosus. J Miss State Med Assoc 52(2):39\u201343","journal-title":"J Miss State Med Assoc"},{"key":"2074_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell Discov"},{"key":"2074_CR50","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71:732\u2013739. https:\/\/doi.org\/10.1093\/cid\/ciaa237","journal-title":"Clin Infect Dis"},{"key":"2074_CR51","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"2074_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https:\/\/doi.org\/10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"issue":"4","key":"2074_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","volume":"30","author":"JM Rolain","year":"2007","unstructured":"Rolain JM, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30(4):297\u2013308. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.05.015","journal-title":"Int J Antimicrob Agents"},{"key":"2074_CR54","doi-asserted-by":"publisher","unstructured":"Devaux CA, Rolain JM, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents:105938. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105938","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"issue":"11","key":"2074_CR55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/s1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3(11):722\u2013727. https:\/\/doi.org\/10.1016\/s1473-3099(03)00806-5","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2074_CR56","doi-asserted-by":"publisher","DOI":"10.3171\/2014.12.FOCUS14748","volume":"38","author":"EB Golden","year":"2015","unstructured":"Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC (2015) Quinoline- based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 38(3):E12. https:\/\/doi.org\/10.3171\/2014.12.FOCUS14748","journal-title":"Neurosurg Focus"},{"key":"2074_CR57","doi-asserted-by":"publisher","unstructured":"Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM (2020) Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. https:\/\/doi.org\/10.7326\/M20-2496","DOI":"10.7326\/M20-2496"},{"key":"2074_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA et al (2020) A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 383:517\u2013525. https:\/\/doi.org\/10.1056\/NEJMoa2016638","journal-title":"N Engl J Med"},{"key":"2074_CR59","unstructured":"National Institutes of Health (2020) Coronavirus (COVID-19). https:\/\/www.nih.gov\/health- information\/coronavirus. Accessed April 11, 2020"},{"issue":"5","key":"2074_CR60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.572905","volume":"43","author":"MW Hull","year":"2011","unstructured":"Hull MW, Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43(5):375\u2013388","journal-title":"Ann Med"},{"key":"2074_CR61","doi-asserted-by":"crossref","unstructured":"Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, Choe K-W, Kang YM et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6)","DOI":"10.3346\/jkms.2020.35.e79"},{"key":"2074_CR62","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"2074_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N, Shang J, Jiang S, Du L (2020) Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 11:298. https:\/\/doi.org\/10.3389\/fmicb.2020.00298","journal-title":"Front Microbiol"},{"key":"2074_CR64","doi-asserted-by":"crossref","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L (2020) Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv","DOI":"10.1101\/2020.02.19.956235"},{"issue":"7","key":"2074_CR65","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.4049\/jimmunol.178.7.4402","volume":"178","author":"E Estefan\u00eda","year":"2007","unstructured":"Estefan\u00eda E, Flores R, G\u00f3mez-Lozano N, Aguilar H, L\u00f3pez-Botet M, Vilches C (2007) Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol (Baltimore, Md : 1950) 178(7):4402\u20134410. https:\/\/doi.org\/10.4049\/jimmunol.178.7.4402","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"key":"2074_CR66","doi-asserted-by":"publisher","unstructured":"Cunningham L, Kimber I, Basketter DA, McFadden JP (2020) Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection. Autoimmun Rev:102563 https:\/\/doi.org\/10.1016\/j.autrev.2020.102563","DOI":"10.1016\/j.autrev.2020.102563"},{"issue":"5","key":"2074_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/gene.2008.39","volume":"9","author":"Z Du","year":"2008","unstructured":"Du Z, Sharma SK, Spellman S, Reed EF, Rajalingam R (2008) KIR2DL5 alleles mark certain combination of activating KIR genes. Genes Immun 9(5):470\u2013480. https:\/\/doi.org\/10.1038\/gene.2008.39","journal-title":"Genes Immun"},{"key":"2074_CR68","unstructured":"Shaikh S, Rao A, Prasad P (2020) Indians do not have genetic protection against coronavirus, published research incorrectly interpreted."},{"issue":"2","key":"2074_CR69","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/v2020574","volume":"2","author":"L Lopalco","year":"2010","unstructured":"Lopalco L (2010) CCR5: from natural resistance to a new anti-HIV strategy. Viruses 2(2):574\u2013600. https:\/\/doi.org\/10.3390\/v2020574","journal-title":"Viruses"},{"issue":"12","key":"2074_CR70","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861\u2013874. https:\/\/doi.org\/10.1038\/nrg3074","journal-title":"Nat Rev Genet"},{"issue":"9","key":"2074_CR71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrneph.2014.116","volume":"10","author":"M Kato","year":"2014","unstructured":"Kato M, Natarajan R (2014) Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol 10(9):517\u2013530. https:\/\/doi.org\/10.1038\/nrneph.2014.116","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2074_CR72","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/nyas.12758","volume":"1353","author":"M Kato","year":"2015","unstructured":"Kato M, Natarajan R (2015) MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci 1353(1):72\u201388. https:\/\/doi.org\/10.1111\/nyas.12758","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2074_CR73","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/er.2016-1122","volume":"38","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Sun X, Icli B, Feinberg MW (2017) Emerging roles for microRNAs in diabetic microvascular disease: novel targets for therapy. Endocr Rev 38(2):145\u2013168. https:\/\/doi.org\/10.1210\/er.2016-1122","journal-title":"Endocr Rev"},{"key":"2074_CR74","doi-asserted-by":"publisher","unstructured":"Song R, Hu XQ, Zhang L (2019) Mitochondrial MiRNA in cardiovascular function and disease. Cells 8(12). https:\/\/doi.org\/10.3390\/cells8121475","DOI":"10.3390\/cells8121475"},{"issue":"6","key":"2074_CR75","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1096\/fba.2018-00064","volume":"1","author":"Q Cao","year":"2019","unstructured":"Cao Q, Chen XM, Huang C, Pollock CA (2019) MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: an update. FASEB Bioadv 1(6):375\u2013388. https:\/\/doi.org\/10.1096\/fba.2018-00064","journal-title":"FASEB Bioadv"},{"issue":"367","key":"2074_CR76","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/stke.3672007re1","volume":"2007","author":"RJ Jackson","year":"2007","unstructured":"Jackson RJ, Standart N (2007) How do microRNAs regulate gene expression? Science's STKE: Signal Transduction Knowledge Environment 2007(367):re1. https:\/\/doi.org\/10.1126\/stke.3672007re1","journal-title":"Science's STKE: Signal Transduction Knowledge Environment"},{"issue":"14","key":"2074_CR77","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","volume":"124","author":"RL Montgomery","year":"2011","unstructured":"Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA et al (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14):1537\u20131547. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030932","journal-title":"Circulation"},{"issue":"6","key":"2074_CR78","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/eurjhf\/hft018","volume":"15","author":"BA Dickinson","year":"2013","unstructured":"Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG et al (2013) Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 15(6):650\u2013659. https:\/\/doi.org\/10.1093\/eurjhf\/hft018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2074_CR79","doi-asserted-by":"publisher","first-page":"H33","DOI":"10.1152\/ajpheart.00341.2016","volume":"312","author":"MV Pinti","year":"2017","unstructured":"Pinti MV, Hathaway QA, Hollander JM (2017) Role of microRNA in metabolic shift during heart failure. Am J Phys Heart Circ Phys 312(1):H33\u2013H45. https:\/\/doi.org\/10.1152\/ajpheart.00341.2016","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"8","key":"2074_CR80","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2016) Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8(8):959\u2013970. https:\/\/doi.org\/10.2217\/imt-2016-0020","journal-title":"Immunotherapy"},{"key":"2074_CR81","doi-asserted-by":"publisher","unstructured":"immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents:105982 https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105982","DOI":"10.1016\/j.ijantimicag.2020.105982"},{"key":"2074_CR82","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","volume":"31","author":"JM Michot","year":"2020","unstructured":"Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B et al (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 31:961\u2013964. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.300","journal-title":"Ann Oncol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-02074-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:20:10Z","timestamp":1629246010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-02074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":82,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-02074-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}